Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 23142081
Kim SJ, et al. (2012) mTOR Complex 2 Regulates Proper Turnover of Insulin Receptor Substrate-1 via the Ubiquitin Ligase Subunit Fbw8. Mol Cell 48, 875-87 23142081
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S86-p - FBXW8 (mouse)
Modsite: DTSSRsRsPPDRDAt SwissProt Entrez-Gene
Orthologous residues
FBXW8 (human): S85‑p, FBXW8 (mouse): S86‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE mTOR (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE mTOR (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, microscopy-colocalization
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Sin1 (human) increase Sin1 KO decreases
rapamycin decrease
Torin1 decrease
siRNA augment treatment-induced decrease mTORC2 siRNA
Downstream Regulation
Effect of modification (function):  intracellular localization, protein stabilization

S302-p - IRS1 (mouse)
Modsite: TRRSRtEsITAtsPA SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S307‑p, IRS1 (mouse): S302‑p, IRS1 (rat): S302‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE mTOR (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, microscopy-colocalization
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
serum Sin1 (human) inhibit treatment-induced increase Sin1 KO augments treatment
rapamycin decrease
Torin1 decrease
siRNA augment treatment-induced decrease mTORC2 siRNA

S632-p - IRS1 (mouse)
Modsite: NGDyMPMsPKsVsAP SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S636‑p, IRS1 (mouse): S632‑p, IRS1 (rat): S632‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), L6 (myoblast), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE mTOR (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, microscopy-colocalization
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
serum Sin1 (human) inhibit treatment-induced increase Sin1 KO augments treatment
rapamycin decrease
rapamycin Sin1 (human) augment treatment-induced decrease
Torin1 decrease
insulin increase
siRNA decrease mTORC2 siRNA
rapamycin insulin inhibit treatment-induced increase
Torin1 insulin inhibit treatment-induced increase
IGF-1 increase
dactolisib insulin inhibit treatment-induced increase
MG132 insulin augment treatment-induced increase
Downstream Regulation
Effect of modification (function):  protein degradation

S635-p - IRS1 (mouse)
Modsite: yMPMsPKsVsAPQQI SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S639‑p, IRS1 (mouse): S635‑p, IRS1 (rat): S635‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), L6 (myoblast), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE mTOR (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, microscopy-colocalization
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
serum Sin1 (human) inhibit treatment-induced increase Sin1 KO augments treatment
rapamycin decrease
rapamycin Sin1 (human) augment treatment-induced decrease
Torin1 decrease
insulin increase
siRNA decrease mTORC2 siRNA
rapamycin insulin inhibit treatment-induced increase
Torin1 insulin inhibit treatment-induced increase
IGF-1 increase
dactolisib insulin inhibit treatment-induced increase
MG132 insulin augment treatment-induced increase
Downstream Regulation
Effect of modification (function):  protein degradation